{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:10:48Z","timestamp":1790007048058,"version":"4.0.1"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.reth.2026.101112","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:09:46Z","timestamp":1776755386000},"page":"101112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["From production to bedside: A tiered QC framework for regulatory alignment and analytical comparability in decentralized CGT"],"prefix":"10.1016","volume":"32","author":[{"given":"Sagi","family":"Nahum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4681-8728","authenticated-orcid":false,"given":"Devanshi","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4240-9003","authenticated-orcid":false,"given":"Cris","family":"Kosnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Jeffries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko von der","family":"Leyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reth.2026.101112_bib1","first-page":"1460","article-title":"Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy","volume":"109","author":"Jallouk","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.reth.2026.101112_bib2","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.reth.2026.101112_bib3","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/bloodadvances.2024015732","article-title":"Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.reth.2026.101112_bib4","doi-asserted-by":"crossref","first-page":"1082.e1","DOI":"10.1016\/j.jtct.2024.09.007","article-title":"Real-world analysis of barriers to timely administration of chimeric antigen receptor T cell (CAR T) therapy in diffuse large B-cell lymphoma","volume":"30","author":"Hu","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.reth.2026.101112_bib5","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/bjh.70090","article-title":"Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma","volume":"207","author":"Morimoto","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.reth.2026.101112_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.xphs.2021.08.032","article-title":"Re-Envisioning pharmaceutical manufacturing: increasing agility for global patient access","volume":"111","author":"Algorri","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.reth.2026.101112_bib7","doi-asserted-by":"crossref","DOI":"10.1116\/1.5013335","article-title":"Enhancing cell and gene therapy manufacture through the application of advanced fluorescent optical sensors","volume":"13","author":"Harrison","year":"2018","journal-title":"Biointerphases"},{"key":"10.1016\/j.reth.2026.101112_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1591751","article-title":"Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations","volume":"12","author":"von der Leyen","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.reth.2026.101112_bib9","series-title":"The human medicines (Amendment) (Modular manufacture and point of care) regulations 2025","year":"2025"},{"key":"10.1016\/j.reth.2026.101112_bib10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jcyt.2017.07.005","article-title":"Decentralized manufacturing of cell and gene therapies: overcoming challenges and identifying opportunities","volume":"19","author":"Harrison","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101112_bib11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00170-019-04516-1","article-title":"Distributed automated manufacturing of pluripotent stem cell products","volume":"106","author":"Shariatzadeh","year":"2020","journal-title":"Int J Adv Manuf Technol"},{"key":"10.1016\/j.reth.2026.101112_bib12","article-title":"Distributed manufacturing of drugs: stakeholder feedback and action plan","year":"2023","journal-title":"Code Fed Regul"},{"key":"10.1016\/j.reth.2026.101112_bib13","series-title":"Human medicines modular manufacture and point of care regulations 2025: overview","year":"2025"},{"key":"10.1016\/j.reth.2026.101112_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12967-022-03238-5","article-title":"Point-of-care cell therapy manufacturing; it's not for everyone","volume":"20","author":"Stroncek","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.reth.2026.101112_bib15","doi-asserted-by":"crossref","DOI":"10.2196\/17005","article-title":"Developing a blockchain-based supply chain system for advanced therapies: protocol for a feasibility study","volume":"9","author":"Lam","year":"2020","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.reth.2026.101112_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.seminhematol.2023.01.001","article-title":"Place of care manufacturing of chimeric antigen receptor cells: opportunities and challenges","volume":"60","author":"Orentas","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.reth.2026.101112_bib17","article-title":"Guidance for industry: chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs)","year":"2020","journal-title":"Code Fed Regul"},{"key":"10.1016\/j.reth.2026.101112_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21290-5","article-title":"A digital platform for the design of patient-centric supply chains","volume":"12","author":"Triantafyllou","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.reth.2026.101112_bib19","article-title":"CAR-T cell therapy for hematological malignancies: history, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.reth.2026.101112_bib20","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.reth.2026.101112_bib21","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","article-title":"Expanding access to CAR T cell therapies through local manufacturing Nature Biotechnology","volume":"41","author":"Elsallab","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.reth.2026.101112_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"key":"10.1016\/j.reth.2026.101112_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","article-title":"Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility","volume":"23","author":"Gupta","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.reth.2026.101112_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1397613","article-title":"Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma","volume":"14","author":"Medina-Olivares","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.reth.2026.101112_bib25","series-title":"Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products","year":"2018"},{"key":"10.1016\/j.reth.2026.101112_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41417-019-0157-z","article-title":"Autologous CAR T-cell therapies supply chain: challenges and opportunities?","volume":"27","author":"Papathanasiou","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.reth.2026.101112_bib27","series-title":"Questions and answers comparability considerations for Advanced Therapy Medicinal Products (ATMP)","year":"2019"},{"key":"10.1016\/j.reth.2026.101112_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.918565","article-title":"Optimization of Mesenchymal Stromal Cell (MSC) manufacturing processes for a better therapeutic outcome","volume":"13","author":"Fern\u00e1ndez-Santos","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.reth.2026.101112_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1608194","article-title":"Identification of critical process parameters and quality attributes for bioreactor-based expansion of human MSCs","volume":"13","author":"Herbst","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.reth.2026.101112_bib30","series-title":"EudraLex Volume 4, EU guidelines for good manufacturing practice for medicinal products for human and veterinary use Annex 1: manufacture of Sterile medicinal products","first-page":"1","year":"2022"},{"key":"10.1016\/j.reth.2026.101112_bib31","series-title":"EudraLex volume 4, Annex 1: manufacture of sterile medicinal products","year":"2022"},{"key":"10.1016\/j.reth.2026.101112_bib32","series-title":"Potency assurance for cellular and gene therapy products \u2014 draft guidance for industry","year":"2023"},{"key":"10.1016\/j.reth.2026.101112_bib33","article-title":"Comparability protocols for human drugs and biologics: chemistry, manufacturing, and controls information guidance for industry","year":"2016","journal-title":"Code Fed Regul"},{"key":"10.1016\/j.reth.2026.101112_bib34","series-title":"Manufacturing changes and comparability for human cellular and gene therapy products; draft guidance for industry. US Department of health and human services","year":"2023"},{"key":"10.1016\/j.reth.2026.101112_bib35","series-title":"Distributed manufacturing and point-of-care manufacturing of drugs","year":"2022"},{"key":"10.1016\/j.reth.2026.101112_bib36","series-title":"Guideline for comparability of human cell-processed products subject to changes in their manufacturing process","year":"2024"},{"key":"10.1016\/j.reth.2026.101112_bib37","series-title":"Act on the safety of regenerative medicine","year":"2022"},{"key":"10.1016\/j.reth.2026.101112_bib38","series-title":"Pharmaceuticals and medical devices agency (PMDA)","year":"2024"},{"key":"10.1016\/j.reth.2026.101112_bib39","article-title":"Guidance on conditional and time-limited approval for human cell-processed products derived from mesenchymal stem cells or mesenchymal stromal cells of human origin and evaluation for subsequent efficacy evaluation plan","year":"2024","journal-title":"PMDA-MHLW"},{"key":"10.1016\/j.reth.2026.101112_bib40","series-title":"Act on the safety of and support for advanced regenerative medicine and advanced biopharmaceuticals (ARMAB)","year":"2020"},{"key":"10.1016\/j.reth.2026.101112_bib41","series-title":"Regulation on approval and review of biological Products[MFDS notification no. 2015-104]","year":"2015"},{"key":"10.1016\/j.reth.2026.101112_bib42","article-title":"Gaps between Asian regulations for eligibility of human mesenchymal stromal cells as starting materials of cell therapy products and comparability of mesenchymal stromal cell-based products subject to changes in their manufacturing process","volume":"15","author":"Tanaka","year":"2020","journal-title":"Regen Ther"},{"key":"10.1016\/j.reth.2026.101112_bib43","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/rme-2021-0026","article-title":"Comparability: what we can learn from the review of advanced therapy medicinal products","volume":"16","author":"Cockroft","year":"2021","journal-title":"Regen Med"},{"key":"10.1016\/j.reth.2026.101112_bib44","article-title":"Considerations for the development of chimeric antigen receptor (CAR) T cell products: guidance for industry","year":"2024","journal-title":"Code Fed Regul"},{"key":"10.1016\/j.reth.2026.101112_bib45","series-title":"Technical and regulatory considerations for pharmaceutical product lifecycle management Q12","year":"2019"},{"key":"10.1016\/j.reth.2026.101112_bib46","series-title":"Ministerial ordinance on good gene, cellular and tissue-based products manufacturing practice (GCTP)","year":"2014"},{"key":"10.1016\/j.reth.2026.101112_bib47","article-title":"Nonclinical safety studies and clinical studies of regenerative medical products (human cell-processed products)","year":"2016","journal-title":"PMDA-MHLW"},{"key":"10.1016\/j.reth.2026.101112_bib48","series-title":"(Biological products) guideline on the evaluation of biosimilar products biopharmaceuticals and herbal medicine evaluation department","year":"2022"},{"key":"10.1016\/j.reth.2026.101112_bib49","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/app14031303","article-title":"Integrating artificial intelligence for academic advanced therapy medicinal products: challenges and opportunities","volume":"14","author":"Aguilar-Gallardo","year":"2024","journal-title":"Appl Sci"},{"key":"10.1016\/j.reth.2026.101112_bib50","series-title":"Comparability of biotechnological\/biological products subject to changes in their manufacturing process Q5E","year":"2004"},{"key":"10.1016\/j.reth.2026.101112_bib51","series-title":"Q9(R1) quality risk management guidance for industry ICH-quality","year":"2023"},{"key":"10.1016\/j.reth.2026.101112_bib52","series-title":"Q2(R2) validation of analytical procedures guidance for industry ICH-quality revision 2","year":"2024"},{"key":"10.1016\/j.reth.2026.101112_bib53","series-title":"USP <1010>: Analytical data-interpretation and treatment. USP 35\u2013NF 30","year":"2012"},{"key":"10.1016\/j.reth.2026.101112_bib54","article-title":"Frequently asked questions \u2014 developing potential cellular and gene therapy products ; draft guidance for industry","year":"2024","journal-title":"Code Fed Regul"},{"key":"10.1016\/j.reth.2026.101112_bib55","series-title":"General chapter <1226> verification of compendial procedures, United States pharmacopeial convention","year":"2008"},{"key":"10.1016\/j.reth.2026.101112_bib56","article-title":"Analytical procedures and methods validation for drugs and biologics guidance for industry","year":"2015","journal-title":"Code Fed Regul"},{"key":"10.1016\/j.reth.2026.101112_bib57","series-title":"Validation of analytical procedures","year":"2023"},{"key":"10.1016\/j.reth.2026.101112_bib58","series-title":"Guidance for industry: analytical procedures and methods validation for drugs and biologics","year":"2015"},{"key":"10.1016\/j.reth.2026.101112_bib59","series-title":"<1224> transfer of analytical procedures","year":"2012"},{"key":"10.1016\/j.reth.2026.101112_bib60","series-title":"Guidance for industry preclinical assessment of investigational cellular and gene therapy products","year":"2013"},{"key":"10.1016\/j.reth.2026.101112_bib61","series-title":"Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial; guidance for industry","year":"2022"},{"key":"10.1016\/j.reth.2026.101112_bib62","series-title":"Guideline on real time release testing (formerly guideline on parametric release) final","year":"2009"},{"key":"10.1016\/j.reth.2026.101112_bib63","article-title":"USP <1043> ancillary materials for cell, gene, and tissue-engineered products","year":"2020","journal-title":"USP"},{"key":"10.1016\/j.reth.2026.101112_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005457","article-title":"Practical aspects of chimeric antigen receptor T-cell administration: from commercial to point-of-care manufacturing","volume":"13","author":"Martinez-Cibrian","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.reth.2026.101112_bib65","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jcyt.2020.07.006","article-title":"Standards efforts and landscape for rapid microbial testing methodologies in regenerative medicine","volume":"23","author":"Lin-Gibson","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101112_bib66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.biologicals.2019.12.007","article-title":"A highly sensitive internally-controlled real-time PCR assay for mycoplasma detection in cell cultures","volume":"64","author":"Sung","year":"2020","journal-title":"Biologicals"},{"key":"10.1016\/j.reth.2026.101112_bib67","series-title":"A multi-center comparison study between the endosafe \u00ae PTSTM rapid release testing system and traditional test methods for detecting endotoxin in cell therapy products","author":"Gee","year":"2008"},{"key":"10.1016\/j.reth.2026.101112_bib68","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.reth.2026.101112_bib69","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3530148","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in advanced melanoma patients","volume":"2018","author":"Saint-Jean","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.reth.2026.101112_bib70","series-title":"EudraLex volume 4 EU guidelines for good manufacturing practice for medicinal products for human and veterinary use. Annex 15: qualification and validation","year":"2015"},{"key":"10.1016\/j.reth.2026.101112_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2020.05.005","article-title":"Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting","volume":"65","author":"Iancu","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.reth.2026.101112_bib72","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcyt.2020.08.007","article-title":"Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation","volume":"23","author":"Lam","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101112_bib73","article-title":"The cell and gene therapy dilemma centralized Vs. Decentralized","author":"Srivastava","year":"2025","journal-title":"Cell Gene"},{"key":"10.1016\/j.reth.2026.101112_bib74","series-title":"EudraLex: the rules governing medicinal products in the European Union. Volume 4: Good Manufacturing Practice Guidelines on good manufacturing practice specific to advanced therapy medicinal products","year":"2017"},{"key":"10.1016\/j.reth.2026.101112_bib75","first-page":"20852","volume":"vol. 51","year":"2009"},{"key":"10.1016\/j.reth.2026.101112_bib76","series-title":"Consultation on point of care manufacturing","year":"2023"},{"key":"10.1016\/j.reth.2026.101112_bib77","series-title":"Guidance for industry PAT - a framework for innovative pharmaceutical development, manufacturing, and quality assurance","year":"2004"},{"key":"10.1016\/j.reth.2026.101112_bib78","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3343\/alm.2023.0382","article-title":"Manufacturing cell and gene therapies: challenges in clinical translation","volume":"44","author":"Lee","year":"2024","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.reth.2026.101112_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116182","article-title":"Emerging technologies for quality control of cell-based, advanced therapy medicinal products","volume":"246","author":"Zia","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.reth.2026.101112_bib80","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/s12015-022-10373-5","article-title":"Industrialized GMP production of CD34+ cells (ProtheraCytes\u00ae) at clinical scale for treatment of ischemic cardiac diseases is feasible and safe","volume":"18","author":"H\u00e9non","year":"2022","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.reth.2026.101112_bib81","doi-asserted-by":"crossref","first-page":"430","DOI":"10.25082\/JPBR.2023.02.004","article-title":"Blockchain technology for advanced therapy medicinal products: applications in tracking, data sharing, and supply chain automation","volume":"5","author":"Aguilar-Gallardo","year":"2024","journal-title":"J Pharm Biopharm Res"},{"key":"10.1016\/j.reth.2026.101112_bib82","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.reth.2026.101112_bib83","series-title":"Guidance for industry: sterile drug products produced by aseptic processing \u2014 current good manufacturing practice","year":"2004"},{"key":"10.1016\/j.reth.2026.101112_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2025.05.003","article-title":"Artificial intelligence, machine learning, and digitalization systems in the cell and gene therapy sector: a guidance document from the ISCT industry committees","volume":"27","author":"Di Cerbo","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101112_bib85","series-title":"Q2(R2) validation of analytical procedures","year":"2023"},{"key":"10.1016\/j.reth.2026.101112_bib86","article-title":"Data integrity and compliance with drug CGMP questions and answers guidance for industry","year":"2018","journal-title":"Code Fed Regul"},{"key":"10.1016\/j.reth.2026.101112_bib87","article-title":"MHRA \u201cGXP\u201d data integrity guidance and definitions","year":"2018","journal-title":"MHRA"},{"key":"10.1016\/j.reth.2026.101112_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.03.050","article-title":"Redefining quality in cell and gene therapies: lessons from implementing electronic QMS in academic cGMP facility","volume":"33","author":"Wu","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.reth.2026.101112_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202100609","article-title":"Data integrity within the biopharmaceutical sector in the era of Industry 4.0","volume":"17","author":"Alosert","year":"2022","journal-title":"Biotechnol J"},{"key":"10.1016\/j.reth.2026.101112_bib90","article-title":"Digital twins in pharmaceutical and biopharmaceutical manufacturing: a literature review","volume":"8","author":"Chen","year":"2020","journal-title":"Processes MDPI"},{"key":"10.1016\/j.reth.2026.101112_bib91","article-title":"Transformative roles of digital twins from drug discovery to continuous manufacturing: pharmaceutical and biopharmaceutical perspectives","volume":"10","author":"Maharjan","year":"2025","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.reth.2026.101112_bib92","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fmed.2018.00047","article-title":"Application of Raman spectroscopy and univariate modelling as a process analytical technology for cell therapy bioprocessing","volume":"5","author":"Baradez","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.reth.2026.101112_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2022.108048","article-title":"Applications of bio-capacitance to cell culture manufacturing","volume":"61","author":"Bergin","year":"2022","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.reth.2026.101112_bib94","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10529-019-02732-z","article-title":"Automation in cell and gene therapy manufacturing: from past to future","volume":"41","author":"Moutsatsou","year":"2019","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.reth.2026.101112_bib95","series-title":"Guidance for industry process validation: general principles and practices guidance for industry. US Department of Health and human services","first-page":"800","year":"2011"},{"key":"10.1016\/j.reth.2026.101112_bib96","series-title":"ICH Q8(R2): pharmaceutical development","year":"2009"},{"key":"10.1016\/j.reth.2026.101112_bib97","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.biotechadv.2017.12.013","article-title":"Decentralised manufacturing of cell and gene therapy products: learning from other healthcare sectors","volume":"36","author":"Harrison","year":"2018","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.reth.2026.101112_bib98","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1002\/bit.27461","article-title":"Technology outlook for real-time quality attribute and process parameter monitoring in biopharmaceutical development\u2014A review","volume":"117","author":"Wasalathanthri","year":"2020","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.reth.2026.101112_bib99","first-page":"1","article-title":"Your next tech transfer should include these modern tools","author":"Nahum","year":"2023","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.reth.2026.101112_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-72016-8","article-title":"Label-free ghost cytometry for manufacturing of cell therapy products","volume":"14","author":"Teranishi","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.reth.2026.101112_bib101","first-page":"1","article-title":"Accelerating CAR T cell manufacturing with an automated next-day process","volume":"73","author":"Ahmadi","year":"2025","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.reth.2026.101112_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910365","article-title":"Revolutionizing CAR T-Cell therapies: innovations in genetic engineering and manufacturing to enhance efficacy and accessibility","volume":"25","author":"Giorgioni","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.reth.2026.101112_bib103","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/btpr.2199","article-title":"Automated image analysis with the potential for process quality control applications in stem cell maintenance and differentiation","volume":"32","author":"Smith","year":"2016","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.reth.2026.101112_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193498","article-title":"In vitro immunotherapy potency assays using real-time cell analysis","volume":"13","author":"Cerignoli","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.reth.2026.101112_bib105","series-title":"ICH Q14: analytical procedure development","year":"2023"},{"key":"10.1016\/j.reth.2026.101112_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411803","article-title":"CAR-T state of the art and future challenges, A regulatory perspective","volume":"24","author":"Giorgioni","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.reth.2026.101112_bib107","first-page":"24","article-title":"Smart, good manufacturing practice production of cell and gene therapies production of cell and gene therapies A vision for the future","volume":"22","author":"Venkatesan","year":"2024","journal-title":"Bioprocess Int"},{"key":"10.1016\/j.reth.2026.101112_bib108","series-title":"Innovations in pharmaceutical manufacturing on the horizon: Technical challenges, regulatory issues, and recommendations (2021)","year":"2021"},{"key":"10.1016\/j.reth.2026.101112_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.913287","article-title":"Toward rapid, widely available autologous CAR-T cell therapy \u2013 artificial intelligence and automation enabling the smart manufacturing hospital","volume":"9","author":"Hort","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.reth.2026.101112_bib110","series-title":"Considerations for the design of early-phase clinical trials of cellular and gene therapy products guidance for industry","year":"2015"},{"key":"10.1016\/j.reth.2026.101112_bib111","series-title":"Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials","year":"2025"},{"key":"10.1016\/j.reth.2026.101112_bib112","series-title":"Guidance for industry guidance for human somatic cell therapy and gene therapy","year":"1998"},{"key":"10.1016\/j.reth.2026.101112_bib113","series-title":"Guidance for FDA reviewers and sponsors: content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs)","year":"2008"},{"key":"10.1016\/j.reth.2026.101112_bib114","series-title":"Q13 continuous manufacturing of drug substances and drug products guidance for industry","year":"2023"},{"key":"10.1016\/j.reth.2026.101112_bib115","article-title":"Safety testing of human allogeneic cells expanded for use in cell-based medical products","year":"2024","journal-title":"Draft Guidance for Industry"},{"key":"10.1016\/j.reth.2026.101112_bib116","series-title":"ISO 20399 biotechnology-ancillary materials present during the production of cellular therapeutic products and gene therapy products","year":"2022"},{"key":"10.1016\/j.reth.2026.101112_bib117","series-title":"International standard ISO 9001 ISO 9001:2015(E)","year":"2015"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320426000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320426000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:24:09Z","timestamp":1782732249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320426000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":117,"alternative-id":["S2352320426000532"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2026.101112","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From production to bedside: A tiered QC framework for regulatory alignment and analytical comparability in decentralized CGT","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2026.101112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine.","name":"copyright","label":"Copyright"}],"article-number":"101112"}}